Angiotensin II receptor blockers and oral squamous cell carcinoma survival: A propensity-score-matched cohort study

Abstract

Objectives Angiotensin II receptor blockers (ARBs) improve the survival rates of patients with various cancers. However, it remains unclear whether ARBs confer a survival benefit on patients with oral squamous cell carcinoma (OSCC). Here, we assessed the associations between ARB use and survival in patients with OSCC of different stages. Materials and methods This was a 10-year retrospective cohort study of OSCC patients. We enrolled 7,558 patients diagnosed with oral cancer between January 2007 and December 2017 whose details had been entered into the Chang Gung Research Database. Seven hundred and fourteen patients were recruited from the Chang Gung Research Database after performing 1:1 propensity score-matching between ARB users and non-users. Cox’s regression models with adjusted covariates were employed to detect factors influencing the survival rates of patients with OSCC. Results Kaplan-Meier analysis revealed that the overall survival (OS) rate of 180-day ARB users increased (p = 0.038). Cox’s regression models indicated that ARB use, younger patients, early-stage OSCC, and patients without diabetes mellitus were independently prognostic of improved OS. Increased OS was more prominent in 180-day ARB users in stage III, Iva, and IVb categories. Conclusions ARB use for more than 180 days is associated with an increased survival rate and is a positive, independent prognostic factor in patients with OSCC. A further two-arm study should be conducted to confirm the clinical usefulness of ARBs in OSCC patients.

Treatment with Angiotensin-(1-7) Prevents Development of Oral Papilloma Induced in K-ras Transgenic Mice

“…The authors also demonstrated that Ang-(1-7) might reduce tumor growth in NPC xenografts by downregulating the PI3K/Akt/mTOR signaling pathway. Another group assessed the association between the use of AT1 receptor blockers (ARBs) and the survival rates in patients with oral SCC of different stages, showing increased overall survival (OS) rate of ARB users after 180 days of treatment [ 32 ]. Although this suggested an important therapeutic role of Ang-(1-7), since ARBs increase the concentration of the heptapeptide, the effects of Ang-(1-7) in the oral cavity have not been explored.…”

Effect of glycated hemoglobin A1c on the survival of patients with oral squamous cell carcinoma: A multi-institutional database cohort study

“…It has been shown that OSCC patients have a significantly higher comorbidity burden at diagnosis and that survival outcomes are significantly decreased with the presence of additional comorbidities ( 2 , 15 , 16 ). Several hypotheses concerning the underlying biological mechanisms have been suggested for the reduced survival in patients with malignancies.…”

The Value of the Nutritional Indicators in Predicting Free Flap Failure From a Multicentre Database

“…We determined comorbidity status using the criteria of at least 1 instance of coding during hospitalization or at least 3 instances during outpatient visits, as established in previous studies. 13,14 We also collected preoperative laboratory data, such as lymphocyte count, serum albumin, and hemoglobin level. This data was obtained from a blood draw within thirty days before the operation.…”